Teva Pharma Industries Ltd ADR is a drug manufacturers - specialty & generic business based in the US. Teva Pharma Industries Ltd ADR shares (TEVA) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $17.03 – an increase of 1.67% over the previous week. Teva Pharma Industries Ltd ADR employs 37,000 staff and has a trailing 12-month revenue of around $16.8 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $17.03 |
|---|---|
| 52-week range | $9.04 - $19.31 |
| 50-day moving average | $17.81 |
| 200-day moving average | $16.03 |
| Wall St. target price | $22.36 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.85 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $16.81 from 2024-11-19
| 1 week (2024-11-13) | -0.77% |
|---|---|
| 1 month (2024-10-21) | -7.54% |
| 3 months (2024-08-21) | -7.28% |
| 6 months (2024-05-20) | 16.81 |
| 1 year (2023-11-20) | 77.88% |
|---|---|
| 2 years (2022-11-18) | 92.78% |
| 3 years (2021-11-19) | 89.30% |
| 5 years (2019-11-20) | 61.32% |
Valuing Teva Pharma Industries Ltd ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Teva Pharma Industries Ltd ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Teva Pharma Industries Ltd ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2934. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Teva Pharma Industries Ltd ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Teva Pharma Industries Ltd ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.8 billion.
The EBITDA is a measure of a Teva Pharma Industries Ltd ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $16.8 billion |
|---|---|
| Operating margin TTM | 23.18% |
| Gross profit TTM | $7 billion |
| Return on assets TTM | 5.56% |
| Return on equity TTM | -17.52% |
| Profit margin | -5.72% |
| Book value | $5.35 |
| Market Capitalization | $19 billion |
TTM: trailing 12 months
We're not expecting Teva Pharma Industries Ltd ADR to pay a dividend over the next 12 months.
Teva Pharma Industries Ltd ADR's shares were split on a 2:1 basis on 30 June 2004 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Teva Pharma Industries Ltd ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Teva Pharma Industries Ltd ADR shares which in turn could have impacted Teva Pharma Industries Ltd ADR's share price.
Over the last 12 months, Teva Pharma Industries Ltd ADR's shares have ranged in value from as little as $9.04 up to $19.31. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Teva Pharma Industries Ltd ADR's is 0.868. This would suggest that Teva Pharma Industries Ltd ADR's shares are less volatile than average (for this exchange).
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.